PharmGen Science Wins Approval for Pediatric Pranlukast Generic, Targets KRW 14 Billion Market

Secures First Generic in Dry Syrup Formulation... Targets January 2027 Launch

PharmGen Science has secured the first generic version of pranlukast dry syrup for pediatric use and is preparing to enter the market.

PharmGen Science said on October 22 that it had received marketing authorization from the Ministry of Food and Drug Safety for Pranlu Dry Syrup, which contains pranlukast.

PharmGen Science's Bangbae headquarters. PharmGen Science

Pranlu Dry Syrup is a generic developed using the original drug, Citus Dry Syrup, as its reference product, and is the first generic in the pranlukast dry syrup formulation. The company is preparing to enter the market, targeting a launch in January 2027.

Pranlukast is a leukotriene receptor antagonist (LTRA) used to treat bronchial asthma and perennial allergic rhinitis. It suppresses the effects of leukotrienes, which are involved in inflammatory responses, to relieve bronchoconstriction and allergy symptoms.

Pranlu Dry Syrup is taken after being suspended in water, offering a treatment option for pediatric patients who have difficulty swallowing tablets. The company said that its dosage can be adjusted according to body weight, which may make it easier for pediatric patients to take the medication.

The market for pranlukast products has so far been led by Citus Dry Syrup. With generic tablets receiving marketing authorization one after another in recent years and the arrival of the first generic in the dry syrup formulation, competition is expected to intensify.

According to UBIST, a pharmaceutical market research firm, Citus Dry Syrup generated about KRW 12 billion in sales in 2025. The pediatric market for products containing the same active ingredient, including chewable tablets, is estimated at about KRW 14 billion. PharmGen Science plans to target this market, which is primarily made up of pediatric patients, with its launch in 2027.

A PharmGen Science representative said, "As the first generic, we are now able to offer patients a wider range of options."

This content was produced with the assistance of AI translation services.